FDA's VIP Pass for Urgent Drugs: Hearing Seeks Public Input
Published Date: 3/23/2026
Notice
Summary
The FDA is launching a pilot program called the Commissioner's National Priority Voucher (CNPV) to speed up reviews for important new drugs and treatments that tackle big U.S. health challenges. They’re inviting drug makers, experts, and the public to a hearing on June 12, 2026, to share ideas and feedback on how the program should work. This could mean faster approvals and quicker access to life-saving medicines without cutting corners.
Analyzed Economic Effects
6 provisions identified: 2 benefits, 4 costs, 0 mixed.
Ultra-fast FDA review target
The CNPV Pilot Program aims to cut FDA review times for qualifying NDAs, BLAs, and supplements from the typical 10–12 months to a target of 1–2 months. FDA also proposes a filing review target of 14–21 days after receipt of the final application component.
Priority areas that qualify
The program is limited to products that align with specified national priorities: public health crisis response; innovative breakthrough therapies; large unmet medical needs; onshoring and supply chain resilience; and affordability improvements. Only NDAs, BLAs, and manufacturing or efficacy supplements are listed as eligible application types.
Nontransferable voucher rule
CNPV vouchers are nontransferable: they cannot be sold or used for a different application, unlike some traditional priority review vouchers. The voucher grants expedited review for a single application to its recipient only.
Rapid sponsor response and meeting demands
Sponsors accepting a CNPV voucher are expected to respond rapidly to FDA information requests (typically within 24–48 hours), be available for ad hoc meetings during business hours, and facilitate inspections. Labeling negotiations are envisioned to be limited to a maximum of two rounds.
Presubmission, rolling, and submission deadlines
The program asks for presubmission meetings, rolling submissions of CMC information and proposed labeling at least 60 days before final module submission, and recommends limiting manufacturing facilities to no more than 2–3 per submission (with justification required for more). Sponsors are expected to submit a complete application within 2 years of voucher issuance and acknowledge participation or intent to redeem within 2 weeks of issuance.
Eligibility excludes most medical devices
Medical device applications are excluded from the CNPV Pilot Program, though combination products with a drug or biological product primary mode of action may be eligible. The program focuses on drug and biologic applications (NDAs and BLAs) and certain supplements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Previous / Next Documents
Previous: 2026-05572 — Foreign-Trade Zone 27; Application for Subzone; Methods Machine Tools, Inc.; Acton and Sudbury, Massachusetts
Methods Machine Tools, Inc. wants to join Foreign-Trade Zone 27 by adding two new sites in Acton and Sudbury, Massachusetts. This move could help the company save on import taxes and speed up trade, but no production changes are planned yet. Public comments are open until May 4, 2026, so now’s the time to speak up!
Next: 2026-05575 — Announcement of Public Hearing
The National Commission on the Future of the Navy is holding a public hearing on March 25, 2026, to gather ideas from Congress and experts about the Navy’s future. This hearing will shape important decisions about fleet size, shipbuilding, and personnel, affecting how the Navy stays strong and ready. Anyone interested can attend or submit their thoughts by giving advance notice.